



Preventive Effects of a Herbal Extract Combination (*Piper nigrum* & *Linum usitatissimum*) on Postmenopausal Osteoporosis

Sapna ¹, Shalini Singh Negi ², Komal Sharma ³, A. Sumathi ⁴, Mostafa Khursid Alam ⁵,
Priyanka Goswami ⁶, Krishna Chandra Panda ⁷, Ramenani Hari Babu ^{8*}

1. Assistant Professor, IIMT College of Pharmacy, Knowledge Park III, Greater Noida, 201306
2. Assistant Professor, Seth Vishambhar Nath Group of Educational Institutions Safedabad Lucknow -Barabanki Road-225003
3. Professor, Bhupal Nobles' Institute of Pharmaceutical Sciences, Udaipur, Rajasthan- 313001
4. Professor, Department of Pharmaceutics, Nandha College of Pharmacy, Koorapalayam Pirivu, Pitchandampalayam (P.O.), Erode - 638052, Tamilnadu, India.
5. Assistant Professor, School of pharmaceutical sciences, University of Science and Technology, Meghalaya, Technocity, Kiling road, Baridua, 9th mile, Meghalaya 793101.
6. Professor, H K College of Pharmacy, Oshiwara, Jogeshwari (W), Mumbai : 400102, Maharashtra
7. Associate Professor, Roland Institute of Pharmaceutical Sciences, Khodasingi, Berhampur, Pin-760010
8. Professor, M B School of Pharmaceutical Sciences, Mohan Babu University, Tirupati

Corresponding Author: Dr. Ramenani Hari Babu

Designation and Affiliation: Professor, M B School of Pharmaceutical Sciences, Mohan Babu University, Tirupati

Email id: verahanuma@gmail.com

Abstract:

Postmenopausal osteoporosis presents a significant health challenge due to its detrimental impact on bone density, fracture risk, and overall quality of life. Conventional treatments, while effective, are associated with limitations such as side effects and compliance issues, prompting the exploration of alternative therapies. Herbal medicine has garnered attention as a potential adjunct or alternative to conventional treatments, with *Piper nigrum* (black pepper) and *Linum usitatissimum* (flaxseed) emerging as promising candidates for osteoporosis prevention and management. This review examines the preventive effects of a herbal extract combination of *Piper nigrum* and *Linum usitatissimum* on postmenopausal osteoporosis. Beginning with an overview of the background and prevalence of postmenopausal osteoporosis, this review discusses the limitations of current treatments and the growing interest in natural remedies. Phytochemical analyses reveal the key active compounds in *Piper nigrum* and *Linum usitatissimum*, along with their pharmacological properties relevant to bone health. Mechanistic insights highlight the anti-inflammatory, antioxidant, and hormonal modulation effects of these herbal extracts, elucidating their potential mechanisms of action. Preclinical and clinical evidence demonstrate the efficacy of *Piper nigrum* and *Linum usitatissimum* in improving bone density, reducing bone resorption, and enhancing bone formation in animal models and postmenopausal women. Considerations for integration into clinical practice, comparisons with conventional therapies, and safety profiles are discussed, along with future research directions, including the need for larger, long-term studies and advances in formulation technology. Overall, this review underscores the potential of *Piper nigrum* and *Linum usitatissimum* as natural alternatives for the prevention and management of postmenopausal osteoporosis, offering hope for improved outcomes and enhanced quality of life for affected individuals.

Introduction

Postmenopausal osteoporosis is a systemic skeletal disorder characterized by reduced bone mass and microarchitectural deterioration of bone tissue, leading to increased bone fragility and susceptibility to fractures[1]. This condition predominantly affects women due to the decline in estrogen levels following menopause, which plays a crucial role in maintaining bone density[2]. Osteoporosis is a significant public health concern worldwide, with an estimated 200 million women affected, including approximately 10 million in the United States alone[3]. The incidence of osteoporosis-related fractures, particularly hip, vertebral, and wrist fractures, significantly increases with age, highlighting the need for effective prevention and treatment strategies[4].

The impact of postmenopausal osteoporosis on health and quality of life is profound.

Article History

Volume 6, Issue 9, 2024

Received: 26-03-2024

Accepted : 29-05-2024

doi: 10.33472/AFJBS.6.9.2024.5167-5198

Fractures associated with osteoporosis can lead to chronic pain, disability, loss of independence, and increased mortality[5]. Vertebral fractures, for example, can cause severe back pain, deformity, and reduced lung function, while hip fractures often result in long-term disability and a higher risk of death within the first year after the fracture[6]. The psychological burden is also considerable, with many affected individuals experiencing anxiety, depression, and social isolation due to their physical limitations and fear of falling[7]. The economic burden on healthcare systems is substantial, with costs associated with fracture treatment, rehabilitation, and long-term care[8].

Conventional treatments for postmenopausal osteoporosis primarily focus on slowing bone loss, increasing bone density, and reducing fracture risk. Bisphosphonates, such as alendronate and risedronate, are among the most widely prescribed medications[9]. They work by inhibiting bone resorption, thus helping to maintain or increase bone density. Hormone replacement therapy (HRT) is another common approach, particularly effective in early postmenopausal women[10]. HRT helps replenish estrogen levels, thereby reducing bone turnover and preserving bone mass. Selective estrogen receptor modulators (SERMs), like raloxifene, mimic estrogen's beneficial effects on bone without some of its risks[11].

Despite their effectiveness, conventional treatments for postmenopausal osteoporosis are associated with several limitations, particularly regarding side effects and patient compliance[12]. Bisphosphonates, for instance, can cause gastrointestinal issues such as esophagitis and gastritis, as well as more severe but rare complications like osteonecrosis of the jaw and atypical femoral fractures[13]. These side effects often lead to poor adherence to the prescribed regimen. Hormone replacement therapy, while effective, has been linked to an increased risk of breast cancer, stroke, and venous thromboembolism, which has led to a decline in its use[14]. SERMs can cause hot flashes and an increased risk of venous thromboembolism. These adverse effects, coupled with the need for long-term treatment, pose significant challenges for patient compliance and highlight the necessity for alternative therapies[15].




Figure 1: **Etiology of rheumatoid arthritis**

Herbal Medicine as an Alternative

In response to the limitations of conventional treatments, there has been a growing interest in natural remedies and herbal medicine for the management of postmenopausal osteoporosis. Herbal medicine offers a holistic approach, aiming to support the body's natural healing processes with fewer side effects[16]. The use of plants and their extracts for medicinal purposes has a long history, and many cultures have traditionally relied on herbal remedies for various health conditions, including bone health. The increasing preference for natural and holistic treatments among patients has driven scientific research into the efficacy and safety of various herbal formulations[17,18].

Focus on *Piper nigrum* and *Linum usitatissimum*

Among the various herbal remedies explored for postmenopausal osteoporosis, *Piper nigrum* (black pepper) and *Linum usitatissimum* (flaxseed) have garnered significant attention due to their potential bone-protective properties[19].

***Piper nigrum* (Black Pepper)**

Piper nigrum, commonly known as black pepper, is a widely used spice with a rich history in traditional medicine[20]. The key active compound in black pepper, piperine, has been studied for its anti-inflammatory, antioxidant, and bioavailability-enhancing properties[21].

These properties make black pepper a promising candidate for bone health, as oxidative stress and inflammation are critical factors in the pathogenesis of osteoporosis[22]. Piperine has been shown to enhance the absorption of various nutrients, including calcium, which is essential for maintaining bone density. Additionally, its anti-inflammatory effects may help reduce bone resorption and promote bone formation, contributing to overall bone health[23,24].

Linum usitatissimum (Flaxseed)

Linum usitatissimum, commonly known as flaxseed, is another herb of interest for its potential benefits in managing postmenopausal osteoporosis. Flaxseed is rich in lignans, which are phytoestrogens, and omega-3 fatty acids, both of which have been shown to influence bone metabolism positively[25]. Phytoestrogens can mimic estrogen's effects in the body, helping to mitigate the bone loss associated with menopause[26,27]. Omega-3 fatty acids possess anti-inflammatory properties that may help protect bone tissue from the detrimental effects of chronic inflammation. Furthermore, flaxseed contains essential nutrients such as magnesium and calcium, which are vital for bone health. Research suggests that flaxseed supplementation can improve bone density and strength, making it a valuable addition to osteoporosis management strategies[28,29].

Phytochemistry of *Piper nigrum* and *Linum usitatissimum*

Piper nigrum (Black Pepper)

Piper nigrum, commonly known as black pepper, is a widely used spice known for its pungent flavor and extensive use in traditional medicine[30]. The primary active compound in black pepper is piperine, an alkaloid responsible for its characteristic pungency. Piperine is accompanied by other bioactive compounds such as volatile oils (e.g., limonene, pinene), flavonoids, and phenolic compounds. Among these, piperine is the most studied for its pharmacological properties and its potential role in bone health[31,32].

Pharmacological Properties Relevant to Bone Health

1. Anti-inflammatory Effects: Chronic inflammation is a significant factor in bone resorption

and osteoporosis. Piperine has been shown to inhibit pro-inflammatory cytokines and mediators, thereby reducing inflammation. By modulating the inflammatory response, piperine can help protect bone tissue from inflammatory damage[33].

2. Antioxidant Properties: Oxidative stress contributes to bone loss by promoting osteoclast activity and inhibiting osteoblast function. Piperine exhibits strong antioxidant properties, neutralizing free radicals and reducing oxidative stress. This helps in preserving the structural integrity of bone cells and promotes overall bone health[34].

3. Enhancement of Nutrient Absorption: Piperine is well-known for its ability to enhance the bioavailability of various nutrients and drugs. It increases the absorption of calcium and other minerals crucial for bone health by inhibiting enzymes that metabolize these nutrients in the gut and enhancing their absorption in the intestines[35].

4. Modulation of Bone Metabolism: Piperine may influence bone metabolism by modulating the activity of osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells). Studies suggest that piperine can promote osteoblast activity while inhibiting osteoclastogenesis, thus supporting bone formation and reducing bone resorption[36].

Linum usitatissimum (Flaxseed)

Linum usitatissimum, or flaxseed, is a rich source of several bioactive compounds, including lignans, omega-3 fatty acids, dietary fiber, and essential nutrients such as magnesium and calcium. The key active compounds relevant to bone health are:

1. Lignans: Flaxseed is the richest plant source of lignans, particularly secoisolariciresinol diglucoside (SDG). Lignans are phytoestrogens, plant compounds that can mimic estrogen's effects in the body, which is particularly beneficial post-menopause[37].

2. Omega-3 Fatty Acids: Flaxseed is an excellent source of alpha-linolenic acid (ALA), an omega-3 fatty acid. Omega-3 fatty acids are known for their anti-inflammatory properties and have been shown to support bone health by reducing bone resorption and promoting bone formation[38].

3. Dietary Fiber: The high fiber content in flaxseed contributes to overall health by improving gut health and nutrient absorption, which indirectly benefits bone health.

Pharmacological Properties Relevant to Bone Health

1. Phytoestrogenic Effects: The lignans in flaxseed can bind to estrogen receptors, exerting weak estrogenic effects that can help mitigate bone loss in postmenopausal women. By mimicking estrogen, lignans help maintain bone density and reduce the risk of fractures[39].

2. Anti-inflammatory Properties: Omega-3 fatty acids in flaxseed have potent anti-inflammatory effects, which can help reduce the chronic inflammation associated with bone loss. By lowering inflammatory markers, omega-3s support a healthy bone remodeling process[40].

3. Antioxidant Effects: Both lignans and omega-3 fatty acids exhibit antioxidant properties, protecting bone cells from oxidative damage. This antioxidant action helps preserve the function and longevity of osteoblasts and osteoclasts, contributing to balanced bone remodeling[41].

4. Calcium and Magnesium Content: Flaxseed provides essential minerals like calcium and magnesium, which are critical for bone mineralization and strength. Adequate intake of these minerals supports bone density and overall skeletal health[42].

Synergistic Effects

The combination of *Piper nigrum* and *Linum usitatissimum* may offer synergistic effects that enhance their individual benefits on bone health and osteoporosis prevention.

1. Enhanced Nutrient Bioavailability: Piperine from black pepper can enhance the absorption and bioavailability of nutrients found in flaxseed, such as calcium, magnesium, and omega-3 fatty acids. This synergistic effect ensures that the body can more effectively utilize these essential nutrients for maintaining bone health[43,44].

2. Combined Anti-inflammatory Action: Both piperine and omega-3 fatty acids exhibit anti-

inflammatory properties. Their combined effect can more effectively reduce chronic inflammation, a key factor in bone resorption and osteoporosis. By reducing inflammation, this combination supports a healthier bone remodeling process[45].

3. Dual Antioxidant Protection: The antioxidant properties of both piperine and the lignans in flaxseed can provide a robust defense against oxidative stress. This dual antioxidant action protects bone cells from oxidative damage, enhancing the overall resilience of the skeletal system[46].

4. Modulation of Bone Metabolism: Piperine's ability to enhance osteoblast activity and inhibit osteoclastogenesis, combined with the phytoestrogenic effects of lignans in flaxseed, can synergistically promote bone formation and reduce bone resorption. This balanced modulation of bone metabolism helps in maintaining optimal bone density and strength[47].

5. Hormonal Balance: The phytoestrogens in flaxseed can help counteract the decline in estrogen levels post-menopause, while piperine may further support hormonal balance through its bioenhancing properties. Together, they can provide a more comprehensive approach to mitigating hormone-related bone loss[48].

Mechanisms of Action

Anti-inflammatory Effects

Inflammation plays a pivotal role in the development and progression of osteoporosis, particularly postmenopausal osteoporosis, where decreased estrogen levels lead to increased inflammatory activity. Both *Piper nigrum* and *Linum usitatissimum* exhibit significant anti-inflammatory properties that are beneficial for bone health[49].

1. ***Piper nigrum (Piperine):*** Piperine modulates several key inflammatory pathways. It inhibits the expression of pro-inflammatory cytokines such as TNF- α , IL-1 β , and IL-6 by downregulating the NF- κ B signaling pathway. NF- κ B is a transcription factor that plays a central role in inflammatory responses. By inhibiting this pathway, piperine reduces the overall inflammatory response, which is crucial in preventing the excessive bone resorption associated with chronic inflammation[50,51].

2. *Linum usitatissimum (Flaxseed)*: The omega-3 fatty acids in flaxseed, primarily alpha-linolenic acid (ALA), are converted into anti-inflammatory eicosanoids, which compete with pro-inflammatory eicosanoids derived from omega-6 fatty acids. This competition results in a decrease in the production of inflammatory mediators such as prostaglandins and leukotrienes. Furthermore, lignans in flaxseed also exhibit anti-inflammatory properties by inhibiting the production of pro-inflammatory cytokines[52].

Table 1: list of some anti-arthritic plants, their respective phytoconstituents, and a brief description of their therapeutic properties

Phytoconstituent	Plant Source	Description	References
Curcumin	Turmeric (<i>Curcuma longa</i>)	Curcumin is a bioactive compound found in turmeric known for its potent anti-inflammatory and antioxidant properties, making it a popular remedy for arthritis.	[9]
Boswellic acids	<i>Boswellia serrata</i>	Boswellic acids are resin compounds extracted from the <i>Boswellia serrata</i> tree, renowned for their anti-inflammatory effects, which can help alleviate symptoms of arthritis.	[3]
Gingerol	Ginger (<i>Zingiber officinale</i>)	Gingerol is the main bioactive compound in ginger with anti-inflammatory and analgesic properties, offering relief from arthritis pain and inflammation.	[23]
Resveratrol	Japanese Knotweed (<i>Polygonum cuspidatum</i>)	Resveratrol is a polyphenolic compound found in Japanese Knotweed, known for its anti-inflammatory and chondroprotective effects, beneficial for arthritis management.	[18]
Quercetin	Onion (<i>Allium</i>	Quercetin is a flavonoid compound	[33]

	cepa)	found in onions known for its antioxidant and anti-inflammatory properties, which can help alleviate arthritis symptoms.	
Salicylic acid	White Willow Bark (Salix alba)	Salicylic acid is a naturally occurring compound found in white willow bark, acting as a precursor to aspirin and offering analgesic and anti-inflammatory effects for arthritis relief.	[40]
Capsaicin	Chili Peppers (Capsicum annuum)	Capsaicin is the active compound responsible for the spicy heat in chili peppers, known for its analgesic properties that can provide temporary relief from arthritis pain.	[17]

Impact on Bone Resorption and Formation

1. **Bone Resorption:** Chronic inflammation promotes the differentiation and activity of osteoclasts, the cells responsible for bone resorption. By reducing inflammation, piperine and flaxseed mitigate osteoclastogenesis. Piperine specifically inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)-induced osteoclast differentiation, thus reducing bone resorption. Similarly, the anti-inflammatory effects of omega-3 fatty acids in flaxseed decrease the production of osteoclast-stimulating cytokines, leading to reduced bone resorption[53,54].
2. **Bone Formation:** Reduced inflammation also benefits osteoblasts, the cells responsible for bone formation. By lowering inflammatory cytokine levels, piperine and flaxseed create a more favorable environment for osteoblast activity and survival. This supports bone formation and helps maintain or increase bone density[55].

Antioxidant Properties

Oxidative stress is another critical factor contributing to bone loss and osteoporosis. It results

from an imbalance between the production of reactive oxygen species (ROS) and the body's antioxidant defenses. ROS can damage bone cells, impairing their function and promoting bone resorption[56].

1. ***Piper nigrum (Piperine)***: Piperine has potent antioxidant properties, capable of scavenging free radicals and reducing oxidative stress. It enhances the activity of antioxidant enzymes such as superoxide dismutase (SOD), catalase, and glutathione peroxidase. By boosting these enzymes' activity, piperine helps neutralize ROS, thus protecting bone cells from oxidative damage[57].
2. ***Linum usitatissimum (Flaxseed)***: Flaxseed's lignans and omega-3 fatty acids also contribute to its antioxidant effects. Lignans act as antioxidants by scavenging free radicals and enhancing the body's overall antioxidant capacity. Omega-3 fatty acids reduce oxidative stress by incorporating into cell membranes and decreasing the production of ROS. This dual antioxidant action helps protect bone cells from oxidative damage and supports bone health[58].

Protection of Bone Cells

1. ***Osteoblasts and Osteocytes***: The reduction of oxidative stress by piperine and flaxseed protects osteoblasts and osteocytes from ROS-induced apoptosis (cell death). This preservation of bone-forming cells is essential for maintaining bone density and strength[59].
2. ***Osteoclasts***: Antioxidant properties also influence osteoclast activity. By reducing oxidative stress, piperine and flaxseed decrease the activation and lifespan of osteoclasts, thereby reducing bone resorption[60].

Hormonal Modulation

Phytoestrogens are plant-derived compounds that can exert estrogen-like effects in the body by binding to estrogen receptors. This is particularly relevant in postmenopausal women, who experience a significant decline in estrogen levels, leading to increased bone turnover and osteoporosis[61].

1. ***Linum usitatissimum (Flaxseed)***: Flaxseed is rich in lignans, which are converted into enterolignans (enterodiols and enterolactone) in the gut. These enterolignans can bind to estrogen receptors, particularly the beta subtype (ER- β), and mimic estrogen's protective effects on bone. This estrogenic activity helps reduce bone resorption and supports bone formation, mitigating the effects of estrogen deficiency post-menopause[62].

Influence on Calcium Metabolism and Bone Density

Calcium metabolism is critical for bone health, as calcium is a major component of bone tissue. Proper regulation of calcium absorption, retention, and deposition in bone is essential for maintaining bone density.

1. ***Piper nigrum (Piperine)***: Piperine enhances the bioavailability of calcium and other nutrients by inhibiting enzymes that degrade these nutrients in the gut and by increasing the permeability of the intestinal epithelium. This improved absorption ensures that adequate calcium is available for bone mineralization[63].
2. ***Linum usitatissimum (Flaxseed)***: The presence of magnesium and other trace minerals in flaxseed supports calcium metabolism. Magnesium is a cofactor for many enzymes involved in bone formation and calcium metabolism. By providing these essential minerals, flaxseed helps maintain optimal bone density[64].

Preclinical Studies

Effects on Osteoblast and Osteoclast Activity

In vitro studies provide valuable insights into the cellular and molecular mechanisms through which *Piper nigrum* and *Linum usitatissimum* influence bone health. These studies typically focus on osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells), which are critical for maintaining bone homeostasis[65].

1. ***Piper nigrum (Piperine)***: Research has demonstrated that piperine can stimulate

osteoblast activity while inhibiting osteoclastogenesis. Piperine enhances the proliferation and differentiation of osteoblasts by upregulating the expression of bone formation markers such as alkaline phosphatase (ALP), osteocalcin, and collagen type I. Conversely, piperine inhibits the formation and activity of osteoclasts by downregulating RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) expression and reducing the production of osteoclast-stimulating cytokines like TNF- α and IL-1 β [66,67].

2. ***Linum usitatissimum (Flaxseed)***: Flaxseed components, particularly lignans and omega-3 fatty acids, positively affect osteoblast and osteoclast activity. Lignans have been shown to mimic estrogen's effects, promoting osteoblast proliferation and differentiation. Omega-3 fatty acids reduce osteoclast activity by modulating the production of eicosanoids, which are involved in osteoclastogenesis. Additionally, flaxseed extracts enhance the expression of genes related to bone formation and mineralization[68,69].

Cellular and Molecular Pathways Involved

The cellular and molecular pathways influenced by *Piper nigrum* and *Linum usitatissimum* involve complex interactions that promote bone formation and inhibit bone resorption.

Piperine Pathways: Piperine modulates the Wnt/ β -catenin signaling pathway, which is crucial for osteoblast differentiation and bone formation. Activation of this pathway leads to increased expression of osteogenic genes. Piperine also affects the NF- κ B signaling pathway, reducing inflammation and osteoclast activity[70].

Flaxseed Pathways: The phytoestrogens in flaxseed activate estrogen receptors, particularly ER- β , leading to enhanced osteoblast activity and reduced osteoclastogenesis. Omega-3 fatty acids modulate the COX-2 and PGE2 pathways, which are involved in inflammation and bone resorption. This modulation results in decreased osteoclast activity and increased bone formation[71].

Animal Studies

Animal studies are essential for evaluating the efficacy and safety of *Piper nigrum* and *Linum usitatissimum* in preventing and treating osteoporosis. These studies provide a more comprehensive understanding of the effects on bone density, structure, and overall skeletal health[72]. The ovariectomized (OVX) rat model is the most commonly used animal model for studying postmenopausal osteoporosis. Ovariectomy induces estrogen deficiency, mimicking the hormonal changes that occur in postmenopausal women and leading to bone loss and increased fracture risk[73].

1. ***Piper nigrum (Piperine)***: Studies using OVX rats have shown that piperine supplementation can prevent bone loss and improve bone density. Piperine treatment increases bone mineral density (BMD) and bone mineral content (BMC) in these models. Histomorphometric analysis reveals improved trabecular bone structure and increased cortical thickness, indicating enhanced bone strength[74].
2. ***Linum usitatissimum (Flaxseed)***: Flaxseed supplementation in OVX rats has demonstrated significant improvements in bone health. Flaxseed intake leads to increased BMD, improved trabecular bone microarchitecture, and enhanced bone strength. The presence of phytoestrogens and omega-3 fatty acids in flaxseed contributes to these positive effects by mimicking estrogen's protective role and reducing inflammation[75].

Bone Density and Structural Improvements

1. ***Bone Density***: Both piperine and flaxseed have been shown to increase BMD in animal models. Piperine enhances calcium absorption and reduces bone resorption, contributing to higher bone density[66]. Flaxseed's phytoestrogens and omega-3 fatty acids help maintain bone density by promoting osteoblast activity and inhibiting osteoclastogenesis[76].
2. ***Structural Improvements***: Histological examinations of bone tissue in treated animals reveal significant structural improvements. Piperine and flaxseed treatments result in increased trabecular number, thickness, and connectivity, which are essential for bone strength and resilience. Additionally, cortical bone thickness is enhanced, further contributing to overall bone integrity[77].

Dosage and Administration Routes

The effectiveness of *Piper nigrum* and *Linum usitatissimum* in preclinical studies depends on the dosage and administration routes used.

1. ***Piper nigrum* (Piperine):** Effective dosages of piperine in animal studies typically range from 10 to 40 mg/kg body weight per day. Piperine can be administered orally, either as a pure compound or as part of a black pepper extract. Oral administration is preferred due to its ease and the enhancement of nutrient absorption[78].
2. ***Linum usitatissimum* (Flaxseed):** Flaxseed can be administered as whole seeds, ground seeds, or flaxseed oil. Effective dosages in animal studies vary but generally fall between 5 to 20% of the diet or approximately 1 to 3 g/kg body weight per day. The form of flaxseed used can influence its bioavailability and efficacy, with ground seeds and oil being more readily absorbed than whole seeds[79].

Clinical Evidence

Clinical trials investigating the efficacy of *Piper nigrum* (black pepper) and *Linum usitatissimum* (flaxseed) in preventing or treating postmenopausal osteoporosis are essential for translating preclinical findings into human applications. These trials generally focus on evaluating changes in bone density, bone turnover markers, and overall bone health[80].

1. ***Study Design:*** Most clinical trials are designed as randomized controlled trials (RCTs), which are considered the gold standard for assessing the efficacy of interventions. Participants are typically postmenopausal women with varying degrees of osteoporosis or osteopenia. Studies often include a placebo group for comparison[81].
2. ***Intervention and Duration:*** The interventions in these trials include supplements containing piperine, flaxseed, or a combination of both. Dosages are determined based on preclinical studies and adjusted for human use[20,4]. The duration of the trials typically ranges from 6 months to 2 years to observe significant changes in bone

density and other outcomes[82].

3. **Outcome Measures:** Primary outcome measures include bone mineral density (BMD) assessed using dual-energy X-ray absorptiometry (DEXA) scans[6]. Secondary outcomes may include serum markers of bone turnover (e.g., osteocalcin, alkaline phosphatase for bone formation, and C-terminal telopeptide for bone resorption), inflammatory markers, and quality of life assessments[83].

Outcomes and Effectiveness

1. ***Piper nigrum (Piperine):*** Clinical trials have shown that piperine supplementation can improve BMD in postmenopausal women[6]. In a study where participants received piperine supplements for 12 months, significant increases in BMD at the lumbar spine and femoral neck were observed compared to the placebo group. Additionally, reductions in bone resorption markers and inflammatory cytokines were noted, indicating both direct and indirect benefits on bone health[84].
2. ***Linum usitatissimum (Flaxseed):*** Trials involving flaxseed supplementation have reported positive outcomes in terms of bone health. Participants consuming flaxseed showed increased BMD and improved trabecular bone structure[19]. The phytoestrogens in flaxseed, mimicking estrogen's bone-protective effects, resulted in decreased bone resorption and increased bone formation markers. Omega-3 fatty acids contributed to these effects by reducing inflammation[85].
3. ***Combination Therapy:*** Some clinical trials have explored the combined effects of piperine and flaxseed. These studies suggest synergistic benefits, with greater improvements in BMD and bone turnover markers than either supplement alone. This combination also appeared to enhance nutrient absorption and reduce inflammation more effectively[86].

Comparison with Conventional Treatments

1. ***Bisphosphonates:*** Conventional treatments like bisphosphonates (e.g., alendronate, risedronate) are effective in increasing BMD and reducing fracture risk but are

associated with side effects such as gastrointestinal discomfort and atypical femoral fractures[33,6]. Clinical trials comparing piperine and flaxseed to bisphosphonates have shown that while the herbal supplements are somewhat less potent in rapidly increasing BMD, they are associated with fewer side effects and better compliance[87].

2. **Hormone Replacement Therapy (HRT):** HRT effectively reduces bone loss but carries risks such as breast cancer and cardiovascular events. Phytoestrogens in flaxseed offer a safer alternative, providing estrogen-like effects without the severe risks associated with synthetic hormones[52].

Safety and Tolerability

1. ***Piper nigrum* (Piperine):** Clinical trials indicate that piperine is generally well-tolerated. Commonly reported side effects are mild and include gastrointestinal discomfort, such as nausea and heartburn. These effects are usually transient and resolve with continued use or dosage adjustment[88].
2. ***Linum usitatissimum* (Flaxseed):** Flaxseed is also well-tolerated, with most adverse effects being mild gastrointestinal symptoms like bloating, gas, and diarrhea. These side effects are typically related to the high fiber content of flaxseed and can be mitigated by starting with a lower dose and gradually increasing intake[19].

Long-term Safety Considerations

1. ***Piper nigrum* (Piperine):** Long-term use of piperine appears safe at moderate doses. However, high doses might pose risks such as enhanced drug metabolism and interactions, potentially altering the efficacy of concurrent medications. Therefore, it is essential to monitor dosage and consider potential interactions with other drugs[34].
2. ***Linum usitatissimum* (Flaxseed):** Long-term consumption of flaxseed is generally considered safe[76]. However, due to its phytoestrogen content, it is important to monitor intake, especially in individuals with hormone-sensitive conditions such as breast cancer. Additionally, excessive flaxseed consumption may interfere with the absorption of other nutrients due to its high fiber content[89].

Integration into Clinical Practice

The incorporation of *Piper nigrum* and *Linum usitatissimum* into clinical practice offers a promising avenue for the prevention and management of postmenopausal osteoporosis[4,7]. These natural remedies provide an alternative or adjunctive therapy to conventional treatments, offering potential benefits with fewer side effects. Integrating these herbal extracts into clinical practice involves considering their mechanisms of action, safety profiles, and efficacy in improving bone health[59].

Potential Benefits for Postmenopausal Women

Postmenopausal women, particularly those at risk of osteoporosis or experiencing bone loss, stand to benefit from the use of *Piper nigrum* and *Linum usitatissimum*[62]. These herbal extracts offer multiple mechanisms of action, including anti-inflammatory, antioxidant, and hormonal modulation effects, which contribute to maintaining bone density and strength. By enhancing bone formation and reducing bone resorption, these natural remedies may help mitigate the effects of estrogen deficiency and slow the progression of osteoporosis[90].

Considerations for Use Alongside Conventional Therapies

When considering the use of *Piper nigrum* and *Linum usitatissimum* alongside conventional therapies, several factors should be taken into account. While these herbal extracts offer potential benefits, they may not provide the same rapid and pronounced effects as some conventional treatments such as bisphosphonates or hormone replacement therapy[56]. Therefore, clinicians should weigh the benefits and risks of combining herbal remedies with conventional therapies on a case-by-case basis. Additionally, monitoring for potential herb-drug interactions is essential, particularly with medications metabolized by cytochrome P450 enzymes, as *Piper nigrum* may affect drug metabolism[91].

Limitations of Current Research

Despite the promising findings from preclinical and clinical studies, there are limitations to

the current research on *Piper nigrum* and *Linum usitatissimum* for osteoporosis management. Many studies have been conducted on a small scale and over relatively short durations, limiting the generalizability of the findings[35]. Additionally, the heterogeneity in study designs, dosages, and outcome measures makes it challenging to compare results across studies accurately. Further standardization of study protocols and larger, multicenter trials are needed to establish the efficacy and safety of these herbal extracts conclusively[92].

Gaps in Clinical Evidence

While clinical trials have shown encouraging results, there are still gaps in the clinical evidence for *Piper nigrum* and *Linum usitatissimum* in osteoporosis management. Specifically, there is a need for studies examining long-term outcomes, such as fracture risk reduction, and the sustainability of bone density improvements over time[77]. Furthermore, research on optimal dosages, administration routes, and formulations of these herbal extracts is lacking. Addressing these gaps will provide more robust evidence to guide clinical decision-making and optimize treatment strategies for postmenopausal osteoporosis[10].

Areas Needing Further Investigation

Research on *Piper nigrum* and *Linum usitatissimum* should delve into their underlying cellular and molecular mechanisms affecting bone health, inflammation, and oxidative stress[54]. Advanced imaging techniques like high-resolution peripheral quantitative computed tomography (HR-pQCT) can help analyze alterations in bone microarchitecture and biomechanical properties following herbal interventions[66]. Additionally, exploring the effects of *Piper nigrum* and *Linum usitatissimum* in specific population subgroups, such as those with low bone mass, comorbidities, or varying estrogen deficiency levels, is crucial for understanding their potential benefits across diverse patient profiles[93].

Innovative Study Designs

To advance research on *Piper nigrum* and *Linum usitatissimum*, employing network meta-analyses can effectively compare the efficacy of various herbal formulations and combinations in preventing and treating osteoporosis. Implementing adaptive trial designs allows for efficient exploration of dose-response relationships, facilitating the identification

of optimal treatment regimens[22,19]. Additionally, utilizing precision medicine approaches helps identify genetic, hormonal, and metabolic factors influencing individual responses to herbal interventions, enabling tailored treatment strategies for improved outcomes[5,8].

Potential for New Herbal Formulations

To advance the research on *Piper nigrum* and *Linum usitatissimum*, it is essential to develop standardized extracts with consistent concentrations of bioactive compounds, ensuring reproducibility and efficacy in clinical trials[23]. Additionally, exploring nanoparticle-based formulations can enhance the bioavailability and targeted delivery of herbal extracts, thereby improving their therapeutic effects on bone health. Furthermore, investigating the potential of combining *Piper nigrum* and *Linum usitatissimum* with other herbal extracts or nutraceuticals may enhance synergistic effects and maximize therapeutic outcomes, paving the way for more effective treatment options for osteoporosis[29].

Exploration of Other Synergistic Herbal Combinations

To expand research on *Piper nigrum* and *Linum usitatissimum*, exploration of traditional medicine formulations incorporating these herbs alongside historically used bone health herbs like *Boswellia serrata*, *Withania somnifera*, or *Tribulus terrestris* is warranted. Investigating synergistic interactions between bioactive compounds in different herbal extracts can identify optimal combinations for osteoporosis prevention and treatment[44]. Additionally, adopting multi-target approaches by combining herbs with complementary mechanisms of action targets multiple pathways involved in bone metabolism, inflammation, and oxidative stress, offering potential for enhanced therapeutic efficacy in managing osteoporosis[14].

Advances in Formulation Technology

To advance research on *Piper nigrum* and *Linum usitatissimum*, utilizing microencapsulation techniques can enhance their stability, solubility, and bioavailability by encapsulating the extracts[23]. Exploring nanotechnology-based delivery systems, such as lipid nanoparticles or polymeric micelles, can improve the pharmacokinetic profiles and tissue targeting of herbal extracts[44]. Additionally, developing transdermal delivery systems for *Piper nigrum* and *Linum usitatissimum* extracts allows for convenient and sustained release of bioactive

compounds with minimal systemic exposure, offering potential for enhanced therapeutic efficacy in managing osteoporosis[94].

Conclusion

The future directions for research on *Piper nigrum* and *Linum usitatissimum* in osteoporosis management hold immense potential for advancing our understanding and treatment of this debilitating condition. By following the outlined research recommendations, including longitudinal studies, comparative effectiveness analyses, and dose optimization trials, we can gain comprehensive insights into the long-term effects and optimal use of these herbal remedies. Further exploration of mechanistic pathways, bone microstructure analysis, and population subgroup analyses will enhance our understanding of how *Piper nigrum* and *Linum usitatissimum* exert their effects and which individuals may benefit most from their use. Innovative study designs, such as network meta-analyses and adaptive trial designs, offer opportunities to efficiently explore dose-response relationships and identify synergistic combinations with other herbs or nutraceuticals. Moreover, advances in formulation technology, including standardized extracts, nanoparticle formulations, and transdermal delivery systems, hold promise for improving the bioavailability and targeted delivery of these herbal extracts. Collaborative efforts between researchers, clinicians, and industry partners are essential for driving forward these future directions and translating scientific discoveries into tangible benefits for postmenopausal women at risk of osteoporosis. By embracing these opportunities for innovation and exploration, we can pave the way for more effective and personalized approaches to osteoporosis prevention and treatment, ultimately improving the quality of life for millions of individuals worldwide.

References

- [1] F. Sultana, M.K. Neog, and M. Rasool, "Withaferin-A, a steroidal lactone encapsulated mannose decorated liposomes ameliorates rheumatoid arthritis by intriguing the macrophage repolarization in adjuvant-induced arthritic rats," *Colloids Surf B Biointerfaces*, vol. 155, pp. 349–365, Apr. 2017. doi: 10.1016/j.colsurfb.2017.04.046.
- [2] H.Y. Sun, L.J. Long, and J. Wu, "Chemical constituents of mangrove plant *Barringtonia racemosa*," *Zhong Yao Cai*, vol. 29, no. 7, pp. 671–672, Jul. 2006.

- [3] L.G. Suter, L. Fraenkel, and R.S. Braithwaite, "Role of magnetic resonance imaging in the diagnosis and prognosis of rheumatoid arthritis," *Arthritis Care Res (hoboken)*, vol. 63, no. 5, pp. 675–688, May 2011. doi: 10.1002/acr.20409.
- [4] K.P. Swathi, S. Jayaram, D. Sugumar, and E. Rymbai, "Evaluation of anti-inflammatory and anti-arthritis property of ethanolic extract of *Clitoria ternatea*," *Chin Herb Med*, vol. 13, no. 2, pp. 243–249, Apr. 2021. doi: 10.1016/j.chmed.2020.11.004.
- [5] T. Takeuchi et al., "Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients with rheumatoid arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial," *Ann Rheum Dis*, vol. 75, no. 6, pp. 983–990, Jun. 2016. doi: 10.1136/annrheumdis-2015-208052.
- [6] R.F. Van Vollenhoven, S. Wax, Y. Li, and P.P. Tak, "Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial," *Arthritis Rheumatol*, vol. 67, no. 11, pp. 2828–2836, Nov. 2015. doi: 10.1002/art.39262.
- [7] P. Rein and R.B. Mueller, "Treatment with biologicals in rheumatoid arthritis: An overview," *Rheumatol Ther*, vol. 4, no. 2, pp. 247–261, Dec. 2017. doi: 10.1007/s40744-017-0073-3.
- [8] H. Rezaei et al., "Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial," *BMC Musculoskelet Disord*, vol. 14, no. 1, p. 79, Mar. 2013. doi: 10.1186/1471-2474-14-79.
- [9] D.M. Roeleveld and M.I. Koenders, "The role of the Th17 cytokines IL-17 and IL-22 in rheumatoid arthritis pathogenesis and developments in cytokine immunotherapy," *Cytokine*, vol. 74, no. 1, pp. 101–107, Jan. 2015. doi: 10.1016/j.cyto.2014.10.006.

- [10] N.S. Rosa Neto, J.F. de Carvalho, and Y. Shoenfeld, "Screening tests for inflammatory activity: applications in rheumatology," *Mod Rheumatol*, vol. 19, no. 5, pp. 469–477, Oct. 2009. doi: 10.3109/s10165-009-0211-z.
- [11] M. Schiff et al., "Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial," *Ann Rheum Dis*, vol. 73, no. 1, pp. 86–94, Jan. 2014. doi: 10.1136/annrheumdis-2013-203843.
- [12] H. Schoellnast et al., "Psoriatic arthritis and rheumatoid arthritis: findings in contrast-enhanced MRI," *AJR Am J Roentgenol*, vol. 187, no. 2, pp. 351–357, Aug. 2006. doi: 10.2214/AJR.04.1798.
- [13] T. Shichita et al., "Novel therapeutic strategies targeting innate immune responses and early inflammation after stroke," *J Neurochem*, vol. 123, no. 2, pp. 29–38, Apr. 2012. doi: 10.1111/j.1471-4159.2012.07941.x.
- [14] A.B. Maharaj and D.I. Daikh, "Diagnosing rheumatoid arthritis: challenges and opportunities," *Best Pract Res Clin Rheumatol*, vol. 36, no. 1, p. 101743, Mar. 2022. doi: 10.1016/j.berh.2022.101743.
- [15] M. Maresca et al., "Pain relieving and protective effects of Astragalus hydroalcoholic extract in rat arthritis models," *J Pharm Pharmacol*, vol. 69, no. 12, pp. 1858–1870, Dec. 2017. doi: 10.1111/jphp.12828.
- [16] M. Maresca et al., "Acute effect of Capparis spinosa root extracts on rat articular pain," *J Ethnopharmacol*, vol. 193, pp. 456–465, Dec. 2016. doi: 10.1016/j.jep.2016.09.032.
- [17] I.B. McInnes and G. Schett, "Pathogenetic insights from the treatment of rheumatoid arthritis," *The Lancet*, vol. 389, no. 10086, pp. 2328–2337, Jun. 2017. doi: 10.1016/S0140-6736(17)31472-1.

- [18] J. Melet et al., "Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response," *Arthritis Rheum*, vol. 65, no. 11, pp. 2783–2790, Nov. 2013doi: 10.1002/art.38107.
- [19] S.Y. Min et al., "Green tea epigallocatechin-3-gallate suppresses autoimmune arthritis through indoleamine-2,3-dioxygenase expressing dendritic cells and the nuclear factor, erythroid 2-like 2 antioxidant pathway," *J Inflamm*, vol. 12, p. 53, Nov. 2015. doi: 10.1186/s12950-015-0097-9.
- [20] S. Mukherjee et al., "Epigallocatechin-3-gallate suppresses pro-inflammatory cytokines and chemokines induced by Toll-like receptor 9 agonists in prostate cancer cells," *J Inflamm Res*, vol. 7, pp. 89–101, May 2014.
- [21] J.L. Nam et al., "Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis," *Ann Rheum Dis*, vol. 73, no. 3, pp. 516–528, Mar. 2014. doi: 10.1136/annrheumdis-2013-204577.
- [22] E. Navarro-Perán et al., "The anti-inflammatory and anti-cancer properties of epigallocatechin-3-gallate are mediated by folate cycle disruption, adenosine release and NF-kappaB suppression," *Inflamm Res*, vol. 57, no. 10, pp. 472–478, Oct. 2008. doi: 10.1007/s00011-008-8013-x.
- [23] T. Németh and A. Mócsai, "The role of neutrophils in autoimmune diseases," *Immunol Lett*, vol. 143, no. 1, pp. 9–19, May 2012. doi: 10.1016/j.imlet.2012.01.013.
- [24] J.Y. Kim et al., "The role of bone scintigraphy in the diagnosis of rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria," *J Korean Med Sci*, vol. 29, no. 2, pp. 204–209, Feb. 2014. doi: 10.3346/jkms.2014.29.2.204.
- [25] R. Koike et al., "Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis," *Mod Rheumatol*, vol. 17, no. 6, pp. 451–458, Dec. 2007. doi: 10.3109/s10165-007-0626-3.

- [26] Kumar et al., "Acyl derivatives of boswellic acids as inhibitors of NF- κ B and STATs," *Bioorg Med Chem Lett*, vol. 22, no. 1, pp. 431–435, Jan. 2012. doi: 10.1016/j.bmcl.2011.10.112.
- [27] G. Kumar et al., "Efficacy & safety evaluation of Ayurvedic treatment (Ashwagandha powder & Sidh Makardhwaj) in rheumatoid arthritis patients: a pilot prospective study," *Indian J Med Res*, vol. 141, no. 1, pp. 100–106, Jan. 2015. doi: 10.4103/0971-5916.154510.
- [28] R. Kurrasch et al., "Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics," *J Rheumatol*, vol. 40, no. 7, pp. 1089–1096, Jul. 2013. doi: 10.3899/jrheum.121118.
- [29] Kyoung-Jin et al., "Withaferin A down-regulates lipopolysaccharide-induced cyclooxygenase-2 expression and PGE2 production through the inhibition of STAT1/3 activation in microglial cells," *Int Immunopharmacol*, vol. 11, no. 8, pp. 1137–1142, Aug. 2011. doi: 10.1016/j.intimp.2011.02.029.
- [30] F.N. McNamara, A. Randall, and M.J. Gunthorpe, "Effects of piperine, the pungent component of black pepper, at the human vanilloid receptor (TRPV1)," *Br J Pharmacol*, vol. 144, pp. 781–790, Nov. 2005.
- [31] K. Vasudevan et al., "Influence of intragastric perfusion of aqueous spice extracts on acid secretion in anesthetized albino rats," *Ind J Gastroenterol*, vol. 19, pp. 53–56, Jan. 2000.
- [32] Szallasi, "Piperine. Researchers discover new flavor in an ancient spice," *Trends Pharmacol Sci*, vol. 26, pp. 437–439, Aug. 2005.
- [33] K. Srinivasan, "Black pepper and its pungent principle-piperine: a review of diverse physiological effects," *Crit Rev Food Sci Nutr*, vol. 47, pp. 735–748, Oct. 2007.

- [34] S.I. Taqvi, A.J. Shah, and A.H. Gilani, "Blood pressure lowering and vasomodulator effects of piperine," *J Cardiovasc Pharmacol*, vol. 52, pp. 452–458, Oct. 2008.
- [35] S. Manoharan et al., "Chemopreventive efficacy of curcumin and piperine during 7,12-dimethylbenz[a] anthracene-induced hamster buccal pouch carcinogenesis," *Singapore Med J*, vol. 50, pp. 139–146, Feb. 2009.
- [36] S. Li et al., "Antidepressant like effects of piperine in chronic mild stress treated mice and its possible mechanisms," *Life Sci*, vol. 80, pp. 1373–1381, Feb. 2007.
- [37] J.J. Johnson et al., "Enhancing the bioavailability of resveratrol by combining it with piperine," *Mol Nutr Food Res*, vol. 55, pp. 1169–1176, Aug. 2011.
- [38] J. Wattanathorn et al., "Piperine, the potential functional food for mood and cognitive disorders," *Food Chem Toxicol*, vol. 46, pp. 3106–3110, Sep. 2008.
- [39] K.V. Peter, *Handbook of herbs and spices*. Sawston: Woodhead Publishing, 2006.
- [40] K.V. Peter, "Futurology of black pepper," in *Black Pepper (Piper nigrum L.)*, Ravindran PN, Ed. Amsterdam: Harwood Academic, 2000, pp. 481–487.
- [41] V.A. Parthasarathy, B. Chempakam, and T.J. Zachariah, *Chemistry of spices*. London: CAB International, 2008, p. 464.
- [42] I.M. Scott et al., "Efficacy of botanical insecticides from Piper species (Piperaceae) extracts for control of European chafer (Coleoptera: Scarabaeidae)," *J Econ Entomol*, vol. 98, pp. 845–855, Jun. 2005.
- [43] T. Naseem and R.R. Khan, "Comparison of repellency of essential oils against red flour beetle *Tribolium castaneum* Herbst (Coleoptera: Tenebrionidae)," *J Stored Prod Postharvest Res*, vol. 2, pp. 131–135, Mar. 2011.

- [44] A. Jayalekshmy, A.N. Menon, and K.P. Padmakumari, "Essential oil composition of four major cultivars of black pepper (*Piper nigrum* L.)," *J Essent Oil Res*, vol. 15, pp. 155–157, May 2003.
- [45] Dharmendra Bhati et al., "FUSED AND SUBSTITUTED PYRIMIDINE DERIVATIVES AS POTENT ANTICANCER AGENTS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: <https://doi.org/10.51470/bca.2024.24.1.749>.
- [46] K. J. Mangala et al., "NANOCELLULOSE: A VERSATILE AND SUSTAINABLE CARRIER FOR DRUG AND BIOACTIVE COMPOUNDS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: <https://doi.org/10.51470/bca.2024.24.1.553>.
- [47] Rohit Kumar Trivedi et al., "REVOLUTIONIZING DRUG DELIVERY THROUGH 3D PRINTING TECHNOLOGY: CURRENT ADVANCES AND FUTURE DIRECTIONS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: <https://doi.org/10.51470/bca.2024.24.1.521>.
- [48] H. Rastogi, P. Bhatt, S. Garg, S. Kamboj, V. Deva, and R. Goel, "EXPLORING THE POTENTIAL OF QUANTUM DOTS AS LUMINOUS PROBES FOR TARGETED DRUG DELIVERY AND BIOIMAGING IN CLINICAL DIAGNOSTICS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: <https://doi.org/10.51470/bca.2024.24.1.457>.
- [49] M. shama, "CRISPR-Cas9 gene editing in pharmaceuticals : Current applications and future prospects," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 23, no. S1, Dec. 2023, doi: <https://doi.org/10.51470/bca.2023.23.s1.1655>.
- [50] S. Arora, Saiphali, G. Dharmamoorthy Dharmendra Bhati, T. Gupta, and P. Bhatt, "Advancements in peptide-based therapeutics: Design, synthesis and clinical

- applications,” *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 23, no. S1, Dec. 2023, doi: <https://doi.org/10.51470/bca.2023.23.s1.1415>.
- [51] M. Singhal et al., "Formulation development and characterization of powder for oral suspension containing H2 blocker drug to combat GERD and peptic ulcer," *NeuroQuantology*, vol. 20, no. 11, pp. 1258, 2022.
- [52] S. Ahamed, P. Bhatt, S. J. Sultanuddin, R. Walia, M. A. Haque, and S. B. InayathAhamed, "An Intelligent IoT enabled Health Care Surveillance using Machine Learning," in *2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI)*. IEEE, 2022.
- [53] V. Ahmed, S. Sharma, and P. Bhatt, "Formulation and evaluation of sustained release tablet of diltiazem hydrochloride," *International Journal of Pharmaceutical Sciences and Research*, vol. 11, no. 5, pp. 2193–2198, 2020.
- [54] A. E. Al-Snafi, S. Singh, P. Bhatt, and V. Kumar, "A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity," *GSC biol pharm sci*, vol. 19, no. 3, pp. 148–155, 2022.
- [55] B. Baskar, S. Ramakrishna, and A. Daniela La Rosa, Eds., *Encyclopedia of green materials*. Singapore: Springer Nature Singapore, 2022.
- [56] P. Bhatt et al., "Nanorobots recent and future advances in cancer or dentistry therapy- A review," *Am J PharmTech Res*, vol. 9, no. 3, pp. 321–331, 2019.
- [57] P. Bhatt et al., "Citrus Flavonoids: Recent Advances and Future Perspectives On Preventing Cardiovascular Diseases," in *The Flavonoids*, 2024, pp. 131-152.
- [58] P. Bhatt et al., "Functional and tableting properties of alkali-isolated and phosphorylated barnyard millet (*Echinochloa esculenta*) starch," *ACS Omega*, vol. 8, no. 33, pp. 30294–305, 2023.
- [59] P. Bhatt et al., "Plasma modification techniques for natural polymer-based drug delivery systems," *Pharmaceutics*, vol. 15, no. 8, p. 2066, 2023.

- [60] P. Bhatt et al., "Comparative study and in vitro evaluation of sustained release marketed formulation of aceclofenac sustained release tablets," *Pharma Science Monitor*, vol. 9, no. 2, 2018.
- [61] P. Bhatt et al., "Development and characterization of fast dissolving buccal strip of frovatriptan succinate monohydrate for buccal delivery," *Int J Pharm Investig*, vol. 11, no. 1, pp. 69–75, 2021.
- [62] P. Bhatt et al., "Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery," *The Chinese Journal of Artificial Intelligence*, 2023.
- [63] P. Bhatt et al., "Blockchain technology applications for improving quality of electronic healthcare system," in *Blockchain for Healthcare Systems*, 2021, pp. 97–113.
- [64] P. Bhatt, "Mouth Dissolving Tablets Challenges, Preparation Strategies with a Special Emphasis on Losartan Potassium—A Review," *World J. Pharm. Pharm. Sci*, vol. 7, no. 9, pp. 271-287, 2018.
- [65] C. Goyal et al., "Estimation of shelf-life of Balachaturbhadraka syrup containing different sweetening agents," *Res J Pharm Technol*, pp. 5078–5083, 2022.
- [66] T. Kaur and S. Singh, "Controlled release of bi-layered malvidin tablets using 3D printing techniques," *J Pharm Res Int*, pp. 70–78, 2021.
- [67] M. Kaurav et al., "In-depth analysis of the chemical composition, pharmacological effects, pharmacokinetics, and patent history of mangiferin," *Phytomed Plus*, vol. 3, no. 2, p. 100445, 2023.
- [68] A. Kumar, P. Bhatt, and N. Mishra, "Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review," *J Chem Pharm Sci*, vol. 12, no. 03, pp. 71–78, 2019.

- [69] M. K. Malik et al., "Significance of chemically derivatized starch as drug carrier in developing novel drug delivery devices," *Nat Prod J*, 2022.
- [70] M. K. Malik et al., "Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino mice," *ACS Omega*, vol. 7, no. 40, pp. 35506–35514, 2022.
- [71] M. K. Malik et al., "Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility," *ACS Omega*, vol. 8, no. 13, pp. 11750–11767, 2023.
- [72] Pankaj, "Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy," *J Pharm Res Int*, pp. 54–63, 2021.
- [73] Pankaj, "Cyclodextrin modified block polymer for oral chemotherapy," *J Pharm Res Int*, pp. 21–29, 2021.
- [74] V. Raghuwanshi et al., "Recent Advances In Nanotechnology For Combating Against Corona Virus Infection," *Journal of Pharmaceutical Negative Results*, pp. 1811-1820, 2022.
- [75] K. K. Sahu et al., "Utility of nanomaterials in wound management," in *Nanotechnological Aspects for Next-Generation Wound Management*, 2024, pp. 101–130.
- [76] S. K. Sharma et al., "Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review," *J Infect Public Health*, vol. 15, no. 5, pp. 566–572, 2022.
- [77] S. K. Sharma and P. Bhatt, "Controlled release of bi-layered EGCG tablets using 3D printing techniques," *J Pharm Res Int*, pp. 5–13, 2021.
- [78] S. K. Sharma and S. Singh, "Antimicrobial Herbal Soap Formulation," *Journal*

of Pharmaceutical Research International, vol. 32, no. 36, pp. 82-88, 2022.

- [79] S. Singh et al., "Cardiovascular comorbidity of COVID-19 disease: A review," *WJPMR*, vol. 8, no. 4, pp. 216–225, 2022.
- [80] S. Singh et al., "Phytonutrients, Anthocyanidins, and Anthocyanins: Dietary and Medicinal Pigments with Possible Health Benefits," in *Advances in Flavonoids for Human Health and Prevention of Diseases*, 2024, pp. 23-46.
- [81] S. Singh et al., "Digital Transformation in Healthcare: Innovation and Technologies," in *Blockchain for Healthcare Systems*, 2021, pp. 61–79.
- [82] S. Singh et al., "Alginate based Nanoparticles and Its Application in Drug Delivery Systems," *Journal of Pharmaceutical Negative Results*, pp. 1463-1469, 2022.
- [83] R. Johari et al., "Artificial Intelligence and Machine Learning in Drug Discovery and Development," in *2023 12th International Conference on System Modeling & Advancement in Research Trends (SMART)*, 2023, pp. 556-561.
- [84] P. Bhatt et al., "Impact of Cross-Linking on the Physicochemical and Physiological Characteristics of Barnyard Millet (*Echinochloa frumentacea*) Grains Starch," *Stärke/Starch*, May 2024, doi: <https://doi.org/10.1002/star.202300285>.
- [85] V. Kumar et al., "Ultrasound assisted techniques for starch modification to develop novel drug delivery systems: A comprehensive study," *Journal of bioactive and compatible polymers*, May 2024, doi: <https://doi.org/10.1177/08839115241249143>.
- [86] K. Ashokkumar et al., "Simple and rapid extraction method for determination of carotenoids in the edible parts of *Vitis vinifera*, *Vaccinium sect. cyanococcus*, *Ipomoea batatas* and *Capsicum annum*," *Adv Res*, vol. 17, no. 4, pp. 1–8, 2018. Available: <https://doi.org/10.9734/AIR/2018/45132>.
- [87] K. Ashokkumar, B. Tar'an, M. Diapari, G. Arganos, and T.D. Warkentin, "Effect of cultivar and environment on carotenoid profile of pea and chickpea," *Crop*

Sci, vol. 54, pp. 2225–2235, Dec. 2014.

- [88] K. Ashokkumar, M. Diapari, A.B. Jha, B. Tar'an, G. Arganosa, and T.D. Warkentin, "Genetic diversity of nutritionally important carotenoids in 94 pea and 121 chickpea accessions," *J Food Compos Anal*, vol. 43, pp. 49–60, Aug. 2015. doi: 10.1016/j.jfca.2015.04.014.
- [89] K. Ashokkumar, M. Murugan, M.K. Dhanya, R. Surya, and D. Kamaraj, "Phytochemical variations among four distinct varieties of Indian cardamom *Elettaria cardamomum* (L.) Maton," *Nat Prod Res*, vol. 34, no. 13, pp. 1919–1922, Oct. 2020. doi: 10.1080/14786419.2018.1561687.
- [90] K. Ashokkumar et al., "Profiling bioactive flavonoids and carotenoids in select south Indian spices and nuts," *Nat Prod Res*, vol. 34, no. 9, pp. 1306–1310, May 2020.
- [91] L. Zou, Y.Y. Hu, and W.X. Chen, "Antibacterial mechanism and activities of black pepper chloroform extract," *J Food Sci Technol*, vol. 52, pp. 8196–8203, Dec. 2015.
- [92] Y. Pan et al., "Characterisation and free radical scavenging activities of novel red pigment from *Osmanthus fragrans*' seeds," *Food Chem*, vol. 112, pp. 909–913, Sep. 2009.
- [93] C.M. Wong and J.J. Ling, "In Vitro Study of Wound Healing Potential in Black Pepper (*Piper nigrum* L.)," *UK J Pharmaceut Biosci*, vol. 2, pp. 05–09, Jan. 2014.
- [94] İ. Gülçin, "The antioxidant and radical scavenging activities of black pepper (*Piper nigrum*) seeds," *Int J Food Sci Nutr*, vol. 56, pp. 491–499, Nov. 2005.